We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Variant Identified As Better Marker for CV Disease

By LabMedica International staff writers
Posted on 24 Apr 2018
A newly identified subset of a known genetic variant found primarily in individuals of South Asian descent may be a better marker for carriers of heart dysfunction in this population and that individuals with this genetic variant are more likely to develop early signs of hypertrophic cardiomyopathy.

Hypertrophic cardiomyopathy occurs when heart muscle cells enlarge and cause the walls of the ventricles to thicken. More...
The ventricle size often remains normal, but the thickening may block blood flow out of the ventricle and cause the heart to work harder. Hypertrophic cardiomyopathy, also commonly referred to as enlarged heart, can lead to sudden cardiac arrest.

An international team of scientists collaborating with the University of Cincinnati (Cincinnati, OH, USA) screened 2,401 South Asians living in the USA for the genetic variant of myosin-binding protein C, cardiac-type (MYBPC3Δ25bp). In this genotype-phenotype study, individuals of South Asian descent living in the USA from both sexes (36.23% female) with a mean population age of 48.92 years (range, 18-84 years) were recruited. Next-generation sequencing of 174 cardiovascular disease genes was applied to identify additional modifying gene mutations and correlate genotype-phenotype parameters. Cardiomyocytes derived from human-induced pluripotent stem cells were established and examined to assess the role of MYBPC3Δ25bp.

The investigators found that 6%, or 144 individuals, carried the genetic variant. Of that population, 9.6% or 13 individuals also carried the novel MYBPC3 variant D389V on the same single allele. Scientists think the prevalence of both the variant and subset occurring in the population of people of South Asian descent to be 1 in 200 individuals. A higher frequency of missense titin (TTN) variation was found in MYBPC3Δ25bp carriers compared with noncarriers, identifying distinct genetic backgrounds within the MYBPC3Δ25bp carrier group.

Shiv Kumar Viswanathan, PhD, PMP, the study’s lead author, said, “What we are seeing is the genetic variant is probably marking a population and within this group there can be a subpopulation that is even more at risk of cardiomyopathy. If we can predict in that population those who are at higher risk then we can hone in and focus on them and get them to a physician's care faster.” The study was published on April 11, 2018, in the journal JAMA Cardiology.

Related Links:
University of Cincinnati


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.